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The objective of many high-dimensional microarray and RNA-seq
studies is to develop a classifier of cancer patients based on charac-
teristics of their disease. The germinal center B-cell (GCB) classifier
study in lymphoma and the National Cancer Institute’s Director’s
Challenge lung (DC-lung) study are two examples. In recent years,
such classifiers are often developed using regularized regression, such
as the lasso. A critical question is whether a better classifier can be
developed from a larger training set size and, if so, how large the
training set should be. This paper examines these two questions us-
ing an existing sample size method and a novel sample size method
developed here specifically for lasso logistic regression. Both meth-
ods are based on pilot data. We reexamine the lymphoma and lung
cancer data sets to evaluate the sample sizes, and use resampling
to assess the estimation methods. We also study application to an
RNA-seq data set. We find that it is feasible to estimate sample size
for regularized logistic regression if an adequate pilot data set exists.
The GCB and the DC-lung data sets appear adequate, under specific
assumptions. Existing human RNA-seq data sets are by and large in-
adequate, and cannot be used as pilot data. Pilot RNA-seq data can
be simulated, and the methods in this paper can be used for sample
size estimation. A MATLAB program is made available.
1. Introduction. Regularized regression methods, such as the lasso, are
common in the analysis of high-dimensional data [Bi et al. (2014), Zwiener
et al. (2014), Moehler et al. (2013), Zhang et al. (2013)]. Regularized logistic
regression is often used to classify patients into different groups, such as those
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who will versus will not respond to a targeted therapy. While development
of classifiers is a long process [Dyrskjøt (2003), Pfeffer et al. (2009), Hanash,
Baik and Kallioniemi (2011), McShane and Hayes (2012), Simon (2010)],
a critical step in that process is determining the sample size necessary to
adequately train a classifier from high-dimensional data.
In this paper, we look at three microarray data sets to evaluate whether
the sample sizes used were adequate. Also, we examine RNA-seq data and
the potential to determine sample size for this newer technology. We reex-
amine the data of Rosenwald et al. (2002). Under the assumption that the
germinal center B cell (GCB) lymphoma subtype patients are correctly iden-
tified in this study, we examine whether a better classifier can be developed
using the lasso logistic regression and, if so, how large a training set would
be needed to do so. Similarly, for the lung cancer data set of Shedden et
al. (2008), the lasso logistic regression is used to evaluate whether a better
outcome predictor could be developed from a larger data set. Third, we ex-
amine a more dramatic classification difference comparing prostate tumors
to normal prostate tissue [Dettling and Bu¨hlmann (2003)]. We also pro-
vide the assumptions on which these sample size estimates are based. These
assumptions can be used to evaluate important public health planning ques-
tions, such as whether re-running similar studies using RNA-seq technology
is likely to yield improved classification. Finally, we examine an RNA-seq
data set as a proof of principle to assess the potential of these methods on
this new technology. We find that the methods can be effectively applied to
RNA-seq data.
What follows is a brief review of the methodology literature. A more
extensive review for interested readers appears in the Supplement [Safo,
Song and Dobbin (2015)].
The novel approach developed for lasso logistic regression in this paper
uses errors-in-variables (EIV) regression. EIV methods for logistic regression
include simulation extrapolation [SIMEX, Cook and Stefanski (1994)], con-
ditional score [Stefanski and Carroll (1987)], consistent functional methods
[Huang and Wang (2001)], approximate corrected score [Novick and Stefan-
ski (2002)], projected likelihood ratio [Hanfelt and Liang (1995)] and quasi-
likelihood [Hanfelt and Liang (1995)]. We discuss each approach briefly. The
SIMEX EIV method adds additional measurement error to the data, estab-
lishes the trend, and extrapolates back to the no error model using a fitted
polynomial regression; as discussed in Cook and Stefanski (1994), evaluating
the adequacy of a fitted regression requires judgment and is not automatic.
The subjective fitting step can complicate algorithm implementation and
Monte Carlo evaluation of performance. So we do not focus on SIMEX, al-
though we do find SIMEX useful in settings where other EIV methods do not
perform well. The consistent functional method is most valuable in large-
scale studies [Huang and Wang (2000)], which are currently very rare in high
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dimensions with sequencing or microarrays. The logistic model does not fit
the corrected score smoothness assumptions; also, the Monte Carlo corrected
score method is not consistent for logistic regression and implementation of
the method requires programming software with complex number capabili-
ties [Carroll et al. (2006)]. Quasi-likelihood methods can be challenging to
implement for logistic regression. Conditional score methods, on the other
hand, are computationally tractable and relatively easy to implement, and
have shown good finite-sample performance [Carroll et al. (2006)]. We found
the sufficient statistics suggested by Hanfelt and Liang (1995, 1997) to be
more stable for this application than the original conditional score, so we
used this closely related approach.
A practical question when using a sample size method that will be based
on a pilot data set, rather than a parametric model, is whether the pilot
data set is large enough. If the pilot data set is too small, then no classifier
developed on it may be statistically significantly better than chance, which
can be assessed with a permutation test [e.g., Mukherjee et al. (2003)]. But,
even if the classifier developed on the pilot data set is better than chance, the
pilot data set can still be too small to estimate the asymptotic performance
as n→∞ well. This latter is a more complex question. But because it is
practically important, guidelines are developed here for evaluating the pilot
data set size.
The sample size method developed in this paper and the one in Mukherjee
et al. (2003) are based on resampling from a pilot data set or from a sim-
ulated data set if no pilot is available. Resampling is used to estimate the
logistic regression slopes for different sample sizes and the prediction error
variances. Cross-validation (CV) [e.g., Geisser (1993)] is a well-established
method for obtaining nearly unbiased estimates of logistic regression slopes.
Because regularized regression already contains a cross-validation step for
parameter tuning, estimating the logistic regression slope by cross-validation
requires nested (double) cross-validation [e.g., Davison and Hinckley (1997)].
An inner cross-validation loop selects the penalty parameter value, which is
then used in the outer loop to obtain the cross-validated classification scores.
We also found it necessary to center and rescale individual CV batches,
and repeat the CV 20–50 times to denoise the estimates. This process is
termed repeated, centered, scaled cross-validation (RCS-CV). To estimate
prediction error variances, the leave-one-out bootstrap (LOOBS) [Efron and
Tibshirani (1997)] can be used. Modification of standard LOOBS is needed
because of the cross-validation step embedded in the regularized regression.
To avoid information leak, the prediction error variance is estimated by
the leave-one-out nested case-cross-validated (LOO-NCCV-BS) bootstrap
[Varma and Simon (2006)]. The same centering and scaling steps added for
CV were also added to the LOO-NCCV-BS. We call this CS-LOO-NCCV-
BS.
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Regularized regression for high-dimensional data is a very active area of
current research in statistics. Common methods include the lasso [Tibshi-
rani (1996)], the adaptive lasso [Zou (2006)] and the elastic net [Zou and
Hastie (2005)], among many others [Fan and Li (2001), Meier, van de Geer
and Bu¨hlmann (2008), Zhu and Hastie (2004)]. In this paper, the focus
of the simulation studies is on the lasso logistic regression, with selection
of the penalty parameter via the cross-validated error rate. Our sample size
methodology can be used with other regularized logistic regression methods,
but may require modifications, particularly if additional layers of resampling
are involved (e.g., the adaptive lasso).
In the study of lymphoma, we find that there is little room for improve-
ment in the GCB signature. This means that patients who receive treatment
based on this signature would be unlikely to have their treatment changed
as a result of a much larger study using microarrays being conducted. Simi-
larly, in the lung cancer application, we find that larger studies in lung cancer
would not be likely to yield better survival prediction, despite the relatively
poor performance of the classifier. This confirms that, unlike breast cancer,
developing clinically useful gene expression-based lung cancer prognostic
predictors is probably not feasible. In the prostate cancer data set, we find
that the asymptotic accuracy of a classifier that distinguishes tumor from
normal tissue is only around 88%. This accuracy may be viewed as lower
than expected since tumor and normal tissues tend to be very different in
most cancers; whether the low accuracy is due to the high heterogeneity of
prostate tissue and prostate cancer tissue or to possible contamination of
the normal samples with pre-cancerous or undiagnosed cancers, we could
not assess. Finally, we find that these methods can be applied to RNA-seq
data, although the novel method appears to give better estimates. But, un-
fortunately, using our own criteria for the pilot sample size requirements,
publicly available human RNA-seq data sets are inadequate. This informa-
tion supports the notion that there is a critical need to make RNA-seq data
more widely accessible to researchers so that they can plan their studies
properly. We hope this information will move policy makers to place a pri-
ority in finding solutions to the existing privacy concerns with these data
sets.
The paper is organized as follows: Section 2 presents the methodology.
Section 3 presents the results of simulation studies. Section 4 presents the
results of real data analysis and resampling studies. Section 5 presents dis-
cussion and conclusions.
2. Methods.
2.1. The penalized logistic regression model. Each individual in a popu-
lation P belongs to one of two classes, C0 and C1. For individual i, let Yi = 0
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if i ∈ C0 and Yi = 1 if i ∈ C1. One wants to predict Yi based on observed
high-dimensional data gi ∈ℜ
p and clinical covariates zi ∈ ℜ
q. A widely used
model for this setting is the linear logistic regression model,
pi(gi, zi) = P (Yi = 1|gi, zi) = {1 + Exp[−α− δ
′zi − γ
′gi]}
−1,(2.1)
where α ∈ ℜ1, δ ∈ ℜq and γ ∈ ℜp are population parameters.
The negative log-likelihood, given observed data (yi, zi, gi) for i= 1, . . . , n,
is
L(α, δ, γ) =−
n∑
i=1
{yi ln[pi(gi, zi)] + (1− yi) ln[1− pi(gi, zi)]}.
To estimate parameters and reduce the dimension of gi, a regularized re-
gression is often fit. Coefficients are set to zero using the penalized negative
log-likelihood function
Lpenalized(α, δ, γ) = L(α, δ, γ) +
p∑
k=1
λkf(γk),(2.2)
where λk are penalty parameters and f is a loss function. If f(γk) = |γk| and
λk ≡ λ > 0, then the result is lasso logistic regression [Tibshirani (1996)].
The first step of the lasso is to estimate the penalty parameter λ, which is
typically done by cross-validation. The clinical covariates zi are not part of
the feature selection process in equation (2.2), but they can be added to that
process if desired. The regularized regression estimates are the solutions to
(αˆ, δˆ, γˆ) = min
α,δ,γ
Lpenalized(α, δ, γ).(2.3)
The minimum can be found by the coordinate descent algorithm [Friedman
et al. (2008)].
2.2. Predicted classification scores. Consider a training set and indepen-
dent validation set. The training set is
Tj = {(y1, z1, g1), . . . , (yn, zn, gn)}
and the validation set is
Vk = {(Y
v
1 , z
v
1 , g
v
1), . . . , (Y
v
m, z
v
m, g
v
m)}.
The minimization in equation (2.3) based on the data set Tj produces esti-
mates (αˆj , δˆj , γˆj). The model is applied to the validation set Vk, resulting in
estimated scores
{αˆj + δˆ
′
jz
v
i + γˆ
′
jg
v
i }
m
i=1.
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Let W uij = γˆ
′
jg
v
i be the high-dimensional part of the predicted classification
score for individual i in the validation set. That is, the gvi is data from
a high-dimensional technology, such as RNA-seq expression measurements.
Let Xui = γ
′gvi and note that we can write W
u
ij = X
u
i + U
u
ij , where U
u
ij =
(γˆj−γ)
′gvi . (The u superscripts denote unstandardized variables, in contrast
to standardized versions presented below.) The model of equation (2.1) can
be written in the form
P (Y vi = 1|zi, gi) = {1 +Exp[−α− δ
′zvi −X
u
i ]}
−1.
Note that, unlike the standard logistic regression model, the variable Xui
does not have a slope parameter multiple. We could develop the model in
its present form, but it will simplify presentation if we make it look more
like the standard model.
Define µx = EP [X
u
i ] =
∫
γ′gf(g)dµ as the mean of the γ′gi taken across
the target population P , where the high-dimensional vectors have density f
with respect to a measure µ. Similarly, define σ2x =VarP(X
u
i ). If these exist,
then we can standardize the scores
Xi =
Xui − µx
σx
, Uij =
Uuij
σx
, Wij =
W uij − µx
σx
=Xi +Uij ,(2.4)
resulting in the EIV logistic regression model
P (Y vi = 1|zi,Xi) = {1 + Exp[−α− δ
′zvi − µx − σxXi]}
−1
= {1 + Exp[−αx − δ
′zvi − β∞Xi]}
−1,
where αx = α+µx, β∞ = σx. Note that EP [Xi] = 0 and VarP(Xi) = 1. This
is the EIV model of Carroll et al. (2006). With these adjustments, we can
apply EIV methods in a straightforward way.
Suppose we repeatedly draw training sets Tt at random from the popula-
tion P , resulting in T1, T2, . . . . Each time we apply the developed predictor to
the validation set Vk. Each application produces an estimated covariate value
vector Xˆt =Wt of length m and corresponding vector of error values Ut,
where Ut = (U1t, . . . ,Umt)
′ =Wt −Xt. Define En[Ut] = limt0→∞
1
t0
∑t0
t=1Ut
and Varn(Ut) = limt0→∞
1
t0−1
∑t0
t=1(Ut−En[Ut])(Ut−En[Ut])
′, that is, these
are the expectation and variance taken across training samples of size n in
the population. The derivation of the conditional score method is based on
an assumption that the Ut are independent and identically distributed Gaus-
sian with En[Ut] = 0 and Varn(Ut) = Σuu, where Σuu is a positive definite
matrix. This assumption can be divided into three component parts:
(1) The En[Uij |gi] = 0 for i= 1, . . . ,m. Equivalently, En[Wij|gi] =Xi, so
that the estimated values are unbiased estimates of the population values.
Intuitively, if ntrain is large enough to develop a good classifier, then this
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assumption should be approximately true. However, if ntrain is much too
small, then the estimated scores may be more or less random and not cen-
tered at the true values—so that this assumption would be violated. But
the assumption is required for identifiability [Dobbin and Song (2013)]. This
shows that some model violation may be expected for our approach as the
sample size gets small.
(2) The Uij have finite variance. This would be true if g
′
iVarn(γˆj)gi <∞
for each i. So, if the regularized linear predictor γˆj has finite second moments
for training samples of size n, the condition would be satisfied.
(3) The vector (U1j , . . . ,Umj) is multivariate normal. This means that
given Gmat = (g1, . . . , gm), (γˆj − γ)
′Gmat is multivariate normal. This would
be true if γˆj were multivariate normal, and may be approximately true if
conditions under which γˆj converges to a normal distribution are satisfied
[e.g., Bu¨hlmann and van de Geer (2011)].
To further simplify the model, we assume Var(Uj) = σ
2
nRn where Rn is a
correlation matrix; in other words, we assume the prediction error variance
is the same for each individual i.
2.3. Defining the objective. Define βj as the slope (associated with the
Wij) from fitting a logistic regression of Yi on (zi,Wij) across the entire
population P . In other words, βj is the true slope from a logistic regression
that uses the training-set-derived Wij as predictors; note that there is one
well-defined βj for a particular training set. The tolerance is then
Tol(n) = |β∞ −En[βj ]|.
Under regularity conditions the tolerance will be finite and |En[βj ]|< |β∞|,
and limn→∞Tol(n) = 0 [Supplement, Section 5.1, Safo, Song and Dobbin
(2015)]. Note that it is possible to have |En[βj ]|> β∞ in logistic EIV [Ste-
fanski and Carroll (1987)]. Let ttarget be the targeted tolerance. The targeted
sample size ntarget is the solution to
ntarget =min{n|Tol(n)≤ ttarget}.
2.4. Estimation. Resampling is used to search for ntarget nonparametri-
cally. This section outlines each step in the estimation process. More detailed
descriptions appear in the Supplement [Safo, Song and Dobbin (2015)].
2.4.1. Estimation for the full pilot data set. Let npilot be the size of the
pilot data set. The parameter βnpilot =Enpilot [βj ] defined in Section 2.3 can
be estimated by cross-validation [e.g., Geisser (1993)]. Regularized logis-
tic regression requires specification of a penalty parameter [λ in equation
(2.2)]. Selecting this penalty parameter once using the whole data set re-
sults in biased estimates of predicted classification performance [Ambroise
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and McLachlan (2002), Simon et al. (2003)]. Therefore, a nested (double)
cross-validation is required [see, e.g., Davison and Hinkley (1997)]. An inner
loop is used to select the penalty parameter λ; then that penalty parameter is
used in the outer loops to obtain the cross-validated classification scores. Be-
cause the split of the data set into 5 subsets may impact the resulting nested
CV slope estimate, we suggest the RCS-CV method; RCS-CV is defined as
repeating the cross-validation 20–50 times, centering and scaling each cross-
validated batch, and using the mean of these 20–50 cross-validated slopes as
the estimate. Centering and scaling of the cross-validated batches is needed
to reduce error variance due to instability in the lasso regression parameter
estimates (not shown). We recommend 5-fold cross-validation.
The cross-validated scores provide an estimate of the slope for a training
sample of size npilot, which we can denote βˆnpilot . We want to apply errors-
in-variables regression to estimate the tolerance, Tol(npilot), and for that we
also need an estimate of the error variance, σ2npilot =Varnpilot(Uij). The leave-
one-out bootstrap [e.g., Efron and Tibshirani (1997)] can be used to estimate
σ2npilot . Because tuning parameters must be selected in regularized regression,
a nested, case-cross-validated leave-one-out bootstrap (LOO-NCCV-BS) is
required [see, e.g., Varma and Simon (2006)]. Letting Wij,bs represent these
bootstrap scores for i= 1, . . . , npilot and j = 1, . . . , b0, where b0 is the number
of bootstraps for each left-out case, then the estimate of σ2npilot is
σˆ2npilot =
1
npilot(b0 − 1)
npilot∑
i=1
b0∑
j=1
(Wij,bs −W i,·,bs)
2,
where W i,·,bs =
1
b0
∑b0
j=1Wij,bs. As with the CV described in the previous
paragraph, one needs to standardize the cross-validated bootstrap batches
to have mean zero and variance 1. This is the CS-LOO-NCCV-BS proce-
dure. Note that in practice the leave-one-out bootstrap is performed using
a single bootstrap and collating the results appropriately, which reduces the
computation cost [Davison and Hinckley (1997)].
Now the σˆ2npilot is “plugged in” to a univariate EIV logistic regression
which also uses the nested CV predicted classification scores as the Wij
in equation (2.4). The conditional score method of Stefanski and Carroll
(1987), with the Hanfelt and Liang (1997), equation (3), modification, is
used to estimate the asymptotic slope β∞ associated with the Xi. Briefly, if
we write the logistic density of equation (2.3) in the canonical generalized
linear model form
f(yi) = Exp
{
yi(α+ δ
′zi + β∞Xi)− b(α+ δ
′zi + β∞Xi)
a(φ)
+ c(yi, φ)
}
,
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where the functions are a(φ) = 1, b(x) = ln(x), c(yi, φ) = 0, then letting θ =
(α, δ, β∞)
′ the conditional score function for θ has the form
∑
i

 (yi −E[yi|Aθi])zi(yi −E[yi|Aθi])
x˜i(yi −E[yi|Aθi])

 ,
where Aθi =Wij + yiΨβ∞, x˜i is an estimator of Xi based Aθi , and Ψ =
Varnpilot(Uij)a(φ).
The conditional score method produces βˆ∞. The tolerance is then esti-
mated with T̂ol(npilot) = |βˆ∞ − βˆnpilot |.
2.4.2. Estimating tolerance for subsets of the pilot data set. Typically,
T̂ol(npilot) will be larger or smaller than ttarget, the targeted tolerance. In
either case, more information about the relationship between Tol(n) and n is
needed to estimate ntarget. Such information can be obtained by subsampling
from the pilot data set. We suggest 7 subsets with a range of sizes be taken
from the pilot data set. Each subset should be large enough, as defined in
Section 2.5 below. For example, npilot×k/7 for k = 1, . . . ,7 can be used. More
typically, if the pilot data set is not as large, then one may use (npilot/2) +
k/6 ∗ (npilot/2) for k = 0, . . . ,6. If npilot/2 is not large enough, then the pilot
set is probably inadequate.
For each subset size less than npilot, call them n
∗
1, . . . , n
∗
6, take a random
sample from the full data set without replacement. Then apply the procedure
described for the full pilot data set to each subset and obtain T̂ol(n∗k), k =
1, . . . ,6. The only modification we suggest to the original RCS-CV procedure
is that for the 20–50 repetitions, take a different random sample each time.
2.4.3. Estimation of nˆtarget. Analysis of a pilot or simulated data set
produces sample sizes n∗1 < n
∗
2 < · · · < n
∗
7 and corresponding tolerance es-
timates tˆ1 = T̂ol(n
∗
1), . . . , tˆ7 = T̂ol(n
∗
7). Fit the Box–Cox regression model
(tˆκi − 1)/κ = δ0 + δ1n
∗
i + εi to obtain κˆ, and define hˆ(x) = (x
κˆ − 1)/κˆ, κˆ 6= 0
and hˆ(x) = Ln(x), κˆ= 0. Then fit with least squares n∗i = η + ζhˆ(tˆi), which
produces ηˆ and ζˆ. Finally, if ttarget > 0 is the desired tolerance, the sample
size is
nˆtarget = ηˆ+ ζˆhˆ(ttarget).
As discussed above, we recommend estimating each tolerance 20–50 times by
repeated random sampling, say, tˆ1,1, . . . , tˆ1,20 and estimating tˆ1 =
1
20
∑20
i=1 tˆ1,i.
Note that the Box–Cox method requires that only values of ttarget > 0 be
considered. Also, in our modeling context, ttarget ≤ 0 does not make intu-
itive sense since the tolerance should always be positive. Theoretically, the
sample size estimate should be ∞ when ttarget = 0. But, depending on the
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estimates ηˆ, ζˆ, κˆ, this may not be the case. Our advice is that the estimated
sample sizes should increase as ttarget decreases over the range of sample
sizes considered.
2.5. Are there enough samples in the pilot data set? The nested resam-
pling methods in our approach require there be adequate numbers in the sub-
sets. If there are npilot in the pilot data set, then a bootstrap sample will con-
tain on average 0.632×npilot unique samples. A 5-fold case cross-validation
of the bootstrap sample will result in 0.2× 0.632 × npilot = 0.13× npilot in
a validation set. Since the validation set scores will be normalized to have
mean zero and variance 1, we recommend at least 80 samples in the training
set to ensure at least 10 samples in these cross-validated sets. If the class
prevalence is imbalanced, this number should be increased. In particular, we
recommend the following:
Condition 1. If npilot is the size of the pilot data set, then npilot ×
0.13×pilowest ≥ 5, where pilowest is the proportion from the underrepresented
class.
The conditional score methods will not work well as the error variance
gets large. Since the conditional score methods are repeated 20–50 times for
each subset size in the RCS-CV procedure, the stability of these estimates
can be evaluated. Therefore, the following guideline is advised:
Practical guideline 1. If the conditional score errors-in-variables re-
gression estimates display instability for any subsample size, use quadratic
SIMEX errors-in-variables regression instead. An example of instability would
be |mean(βˆ∞)/s.d.(βˆ∞)|< 0.5, where the mean and standard deviation are
taken across the 20–50 replicates.
Resampling-based approaches to sample size estimation require that the
relationship between the asymptotic model and the estimated model can be
adequately estimated from the pilot data set. Trouble can arise if the learning
pattern displayed on the pilot set changes dramatically for sample sizes
larger than the pilot data set. For example, there may be no classification
signal detectable with 3 samples per class, but one is detectable with 50
samples per class. So a pilot data set of 6 would lead to the erroneous
conclusion that the asymptotic error rate is 50%, and any resulting sample
size estimates would likely be erroneous. Similarly, the learning process can
be uneven, so that the asymptotic error rate estimate increases or decreases
as the sample size increases. The latter can happen when some subset of
the features have smaller effects than others and are only detected for larger
sample sizes. To guard against this in simulations, at least, we found that
the following guideline is useful:
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Condition 2. The predictor needs to find the important features re-
lated to the class distinction with power at least 85%.
Our simulation-based software program checks the empirical power for
this condition. In the context of resampling from real data, it is not clear
how one could verify this assumption empirically. But it may be possible to
evaluate the effect size associated with this power by a parametric bootstrap.
2.6. Translating between logistic slope and misclassification accuracy. If
there are no clinical covariates in the model, then the misclassification error
rate for the asymptotic model is [e.g., Efron (1975)]
P (Yi = 1 and α+ β∞Xi ≤ 0) + P (Yi = 0 and α+ β∞Xi > 0)
=
∫
−α/β∞
−∞
eα+β∞Xi
1 + eα+β∞Xi
fx(x)dx+
∫
∞
−α/β∞
1
1 + eα+β∞Xi
fx(x)dx,
where fx(x) is the marginal density of the asymptotic scores across the
population P . By definition, these scores have mean zero and variance one.
If we further assume the scores are Gaussian, then the misclassification rate
can be estimated with
m0∑
i=1
[
eα+β∞xi
1 + eα+β∞xi
]
1(xi ≤−α/β∞) +
m0∑
i=1
[
1
1 + eα+β∞xi
]
1(xi >−α/β∞),
where 1(A) is the indicator function for event A and m0 is a number of
Monte Carlo simulations, and x1, . . . , xm0 are drawn from the distribution
xi ∼Normal(0,1). If covariates are added to the model, then the conditional
distribution of xi|zi needs to be used for the Monte Carlo. If xi is independent
of zi, then the xi could be generated from a standard normal, and the Monte
Carlo equations modified in the obvious way. The Supplement [Safo, Song
and Dobbin (2015)] shows a graph of the no covariate case relationship.
3. Results: Simulation studies. For the simulation studies, high-dimen-
sional data were generated from multivariate normal distributions, both
a single multivariate normal and a mixture multivariate normal with ho-
moscedastic variance. Both multivariate normal settings performed simi-
larly [see Supplement, Safo, Song and Dobbin (2015)], so we just present
one in the paper. The covariance matrices were identity, compound sym-
metric (CS) and autoregressive order 1 [AR(1)], as indicated. Class labels
were generated from the linear logistic regression model of equation (2.1).
Categorical clinical covariate data, when included in simulations, were gen-
erated from a distribution with equal probability assigned to each of three
categories, where categories are correlated with class labels.
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Table 1
Estimates of the asymptotic slope β∞ and corresponding accuracy acc∞ evaluated by
simulations. npilot is the number of samples in the pilot data set. The covariance
structure “Cov” are as follows: AR1 is block autoregressive order 1 in 3 blocks of size 3
(9 informative features) with parameter 0.7; Iden. is identity with 1 block of 1 (1
informative feature). Total of p= 500 features; all noise features independent standard
normal. Summary statistics based on 200 Monte Carlo. More results appear in the
Supplement [Safo, Song and Dobbin (2015)]
Logist. slope Class. Acc.
npilot Cov β∞ mean βˆ∞ acc∞ âcc∞ mean mean σˆ
2
n
mean βˆ
n
300 AR1 2.0 2.07 0.778 0.783 0.43 1.49
400 AR1 2.0 2.01 0.778 0.779 0.35 1.62
300 AR1 3.0 3.04 0.836 0.838 0.32 2.31
400 AR1 3.0 2.93 0.836 0.834 0.27 2.47
300 AR1 4.0 3.95 0.871 0.869 0.28 3.06
400 AR1 4.0 3.88 0.871 0.868 0.23 3.26
300 AR1 5.0 3.77 0.894 0.865 0.25 3.71
400 AR1 5.0 4.81 0.894 0.891 0.21 3.99
300 Iden. 2.0 2.05 0.778 0.781 0.23 1.87
400 Iden. 2.0 2.01 0.778 0.778 0.19 1.90
300 Iden. 3.0 3.02 0.836 0.836 0.17 2.85
400 Iden. 3.0 2.98 0.836 0.835 0.14 2.87
300 Iden. 4.0 3.97 0.871 0.870 0.14 3.72
400 Iden. 4.0 3.92 0.871 0.869 0.12 3.75
300 Iden. 5.0 4.94 0.894 0.893 0.14 4.50
400 Iden. 5.0 4.86 0.894 0.891 0.12 4.55
The asymptotic slope parameter β∞ must be estimated. Table 1 presents
a simulation to evaluate the bias and variance of the asymptotic slope pa-
rameter estimate βˆ∞. Also presented are the corresponding estimates of
asymptotic classification accuracy âcc∞. As can be seen from the table, this
approach does well overall at estimating the asymptotic performance for
these pilot data set sample sizes (300 and 400), asymptotic slopes (2,3,4,5),
multivariate normal high-dimensional data, covariance matrix structures
(Identity, CS [Supplement, Safo, Song and Dobbin (2015)] and AR1) and
numbers of informative features (1 and 9). There is some small bias appar-
ent as the slope becomes large (β∞ = 5), probably reflecting the fact that
large slopes are problematic for EIV logistic regression.
The tolerance associated with the estimated sample size should be within
the user-targeted tolerance. To test this, sample sizes were calculated by
applying the method to simulated pilot data sets. Then, these sample size
estimates were assessed by performing very large pure Monte Carlo studies.
Table 2 presents sample size estimates from our method and sample statistics
from the Monte Carlo (MC) simulations. The mean tolerances from the MC
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Table 2
Evaluation of the sample size estimates from AR(1) and identity covariances. The
number in the pilot data set is 400. β∞ = 4. Identity covariance had one informative
feature, and AR(1) had nine informative features in a block structure of 3 blocks of size 3
with correlation parameter 0.7. Estimates evaluated using 400 Monte Carlo simulations
with the estimated sample size. The mean tolerance from the 400 simulations and the
proportion of the 400 within the specified tolerance are given in the rightmost two
columns. The dimension is p= 500
Cov. ttarget nˆ Mean MC tol. % of MC within tol.
AR1 0.10 1742 0.09 64%
AR1 0.20 986 0.19 62%
AR1 0.30 715 0.27 67%
AR1 0.40 573 0.34 71%
AR1 0.50 484 0.43 72%
AR1 0.60 424 0.49 75%
AR1 0.70 380 0.57 77%
Identity 0.10 509 0.09 79%
Identity 0.20 322 0.10 87%
Identity 0.30 242 0.15 87%
Identity 0.40 194 0.16 92%
Identity 0.50 162 0.21 90%
Identity 0.60 139 0.25 93%
Identity 0.70 121 0.31 91%
are all within the targeted tolerance, indicating that the estimated sample
sizes do achieve the targeted tolerance. The method tends to produce larger
sample size estimates than required with 62%–93% of the true tolerances
within the target (rightmost column). Note that our method guarantees
that the expected slope is within the tolerance, but not that the actual
slope is within the tolerance; this latter would be a stronger requirement.
Implementation of our approach in the presence of clinical covariates was
evaluated. Table 3 shows results when a clinical covariate is included into the
setting. In this case the clinical covariate is also associated with the class
distinction; in particular, in equation (2.1), δ = Ln(2) and zi ∈ {−1,0,1},
with 1/3rd probability assigned to each value. As can be seen by comparison
with Table 2, the addition of the clinical covariate significantly increases the
required sample sizes. For example, the estimated sample size for a tolerance
of 0.20 increases 29%, from 322 to 416. This increase reflects correlation
between the clinical covariate and the class labels. The pure Monte Carlo
evaluations in Table 2 show that the method does still produce adequate
sample size estimates in the presence of the clinical covariate.
Figure 1 is a summarization of results from all the different simulation
studies. Negative values on the y-axis mean the sample size was overesti-
mated, and positive values mean the sample size was underestimated. As
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Table 3
Clinical covariate simulations. One clinical covariate with 3 levels which are associated
with the class distinction. The identity covariance and an asymptotic true slope of
β∞ = 4. The dimension is p= 500. See text for more information
ttarget nˆ Mean MC tol. % of MC within tol.
0.1 592 0.07 80%
0.2 416 0.09 88%
0.3 334 0.12 92%
0.4 284 0.14 91%
0.5 249 0.15 95%
0.6 223 0.17 92%
can be seen in the figure, the sample size estimates are mostly adequate or
conservative. When the estimated sample size required is smaller than the
pilot data set (x-axis values are negative), the resulting tolerance estimates
are adequate or conservative; intuitively, identifying a sample size smaller
than the pilot data set should be relatively easy. When the estimated sam-
ple size required is larger than the pilot data set, the method continues to
perform well overall. The exceptions are in the cases of compound symmet-
Fig. 1. Summary of results of simulations. The x-axis is the base 2 logarithm of the ratio
of the estimated training sample size required divided by the pilot training sample size used.
The y-axis is the average tolerance estimated from pure Monte Carlo simulations minus
the targeted tolerance.
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ric and AR1 covariance with a small slope of 3; in these cases, the y-values
are positive, indicating anti-conservative sample size estimates. The prob-
lem here seems to be the power to detect the features. For the compound
symmetric simulations, the empirical bootstrap power was 7.67/9 = 85.2%,
and for AR1 simulations, the power was 84.7%. Both are near the cutoff of
the 85% power criterion developed in Section 2.5 above. Still, overall, the
method seems to perform well.
3.1. LC and EIV performance in simulations. We evaluated both our
resampling-based method and the resampling-based method of Mukherjee
et al. (2003) using pure Monte Carlo estimation of the truth in simulations.
We will denote their method by LC (for learning curve) and our method by
EIV (for errors-in-variables). Figure 2 shows a comparison of the two meth-
ods under a range of simulation settings. In these simulations, our method
may have an advantage because the logistic regression model was used to
generate the response data. Tolerances of 0.1 and 0.2 were considered since
these are associated with larger training sample sizes than the pilot data set.
Comparing the percentage error of the sample size estimate to an estimate
based on pure Monte Carlo, one can see that the learning curve method has
an error an order of magnitude or more larger than our method. The LC
Fig. 2. Sample size estimates for 6 simulated data sets with tolerance set to 0.1. Compar-
ison of errors-in-variables, learning curve, Dobbin and Simon (2007) (with false positive
rate set to at most 1) and the true values (from pure Monte Carlo). Similar results for
tolerance = 0.2 appear in the Supplement [Safo, Song and Dobbin (2015)]. Y -axis is on
the log scale. Size of pilot data set is 300.
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method tends to consistently overestimate the sample size in these simula-
tions. In sum, the EIV method estimates were closer to the true sample size
values than the LC method estimates across all of these simulations.
Finally, we applied the method of Dobbin and Simon (2007) to the same
data sets. As background, this method assumes a prespecified significance
level cutoff for features, hence, it is not well-suited to the lasso logistic
regression. Some ad hoc procedure is needed to approximate the lasso. We
examined an approach that (1) picks the optimal significance level cutoff
(likely to be anti-conservatively biased because of data re-use), and one
that (2) picks a significance level that controls the expected number of false
positives to be at most 1 (in other words, p-value cutoff 1/n). The sample size
estimates for approach (1) were 126, 404, 366, 116, 404 and 374, for data sets
1–6, respectively. Perhaps not surprisingly, this approach underestimates
the sample size requirement for lasso logistic regression. The sample size
estimates for approach (2), using a grid of size 100, were 6700, 1700, 1600,
8100, 1800 and 1900. The results are similar to those for the learning curve.
4. Real data set applications. The methods are applied to four data
sets. The purpose of the first three applications is two-fold. First, we deter-
mine the adequacy of the sample sizes of these studies using both sample
size methods. Second, since microarray data may violate the normality as-
sumption of the simulations, we evaluate the resampling performance of the
methods as a check on their performance with this nonnormal data. The
purpose of the fourth application is primarily to evaluate the ability of the
methods to estimate sample size on RNA-seq data.
A resampling study can be used to compare estimates from a procedure
to a resampling-based “truth.” Since adequate sample sizes are unknown
on these data sets, it was not feasible to compare sample size estimates to
any corresponding estimated true values. But we can compare the error rate
estimated from a subset of the data set to an independent estimate based
on cross-validation on the whole data set.
4.1. The lymphoma data set. We applied the EIV and the LC method
to the data set of Rosenwald et al. (2002). The classes were germinal center
B-cell lymphoma versus all other types of lymphoma. We used both methods
to evaluate whether the sample size used in this study was adequate, and we
subsetted 5 “pilot data sets” of size 100 at random from this data set. For
each of these “pilot data sets,” we estimated the performance when n= 240
are in the training set. Then, we could compare the estimated performance to
a “gold standard” resampling-based performance on the full data set. Results
are shown in Table 4. The two methods agree well on this data set, and both
indicate that on average the pilot data set size of n= 240 provides close to
the optimal accuracy possible, within 0.02. Comparing the two approaches
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Table 4
Resampling studies. Data set is the data set used for resampling. Rep is the replication
number of 5 independent random subsamples (without replacement) of size nPilot. nFull
is the size of the full data set. Classes for the Shedden data set were Alive versus Dead.
Classes for the Rosenwald data set were Germinal-Center B-Cell lymphoma type versus
all others. err(nFull) is estimated from 200 (50 for Shedden) random cross-validation
estimations on the full data set using different partitions each time, and this serves as
the gold standard error rate for nFull. êrr(nFull) is the estimated error rate for the full
data set based on the LC method or EIV method. Similarly, êrr(∞) is the asymptotic
error rate based on the LC method or EIV method. The first column is the dataset, “R”
for Rosenwald and “S” for Shedden. For the Shedden data set, we used conditional score
EIV; for the Rosenwald data set, we used quadratic SIMEX EIV because the criterion for
the conditional score was violated (Section 2.5)
LC method EIV method nFull err %
Data Rep nPilot nFull err(nFull) êrr(nFull) êrr(∞) êrr(nFull) êrr(∞) LC EIV
R 1 100 240 0.1129 0.0855 0.0729 0.1344 0.1135 −25% 19%
R 2 100 240 0.1129 0.0611 0.0435 0.1078 0.0933 −46% −5%
R 3 100 240 0.1129 0.0298 0.0089 0.0771 0.0691 −74% −32%
R 4 100 240 0.1129 0.1443 0.1270 0.1396 0.1379 28% 24%
R 5 100 240 0.1129 0.0682 0.0480 0.0864 0.0783 −40% −23%
Mean 0.1129 0.0778 0.0601 0.1091 0.0984 −31% −3%
S 1 200 443 0.4207 0.4638 0.4634 0.4347 0.4347 10% 3%
S 2 200 443 0.4207 0.4496 0.4481 0.4154 0.4151 7% −1%
S 3 200 443 0.4207 0.4300 0.4258 0.2778 0.2778 2% −34%
S 4 200 443 0.4207 0.4166 0.4126 0.3550 0.3550 −1% −16%
S 5 200 443 0.4207 0.4159 0.4117 0.2907 0.2894 −1% −31%
Mean 0.4207 0.4352 0.4323 0.3548 0.3544 3% −16%
in their ability to estimate the error rate for n= 240 based on a pilot data set
of only n= 100, the EIV method has better mean performance in terms of
estimating the full data set error than the LC method. Here, the differences
are less dramatic than the sample size differences; this may be due to the
sensitivity of sample size methods to relatively small changes in asymptotic
error rates or to the underlying data distribution. Both methods show some
variation in error rate estimates across the five subsets of size 100.
4.2. The lung cancer data set. We next applied both methods to the
lung cancer data set of Shedden et al. (2008), where the classes were based
on survival status at last follow-up. This binary indicator approach was used
for predictors developed in the original paper. In this case, the two methods
produce similar results. Both methods indicate here that on average the
asymptotic performance is extremely close to the full data set performance
when n= 443, with a difference in error rate of less than 0.01. Comparing the
two methods in terms of their ability to estimate the error rate for n= 443
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based on a pilot data set of only n = 200, the LC method was slightly
better on average than the EIV with conditional score based on percentage
error (rightmost columns of table); but the conditional score criterion in
Section 2.5 was exceeded on 3 of the 5 data sets, and if quadratic SIMEX
is used, then the LC and EIV are almost identical [Supplement, Safo, Song
and Dobbin (2015)]. This is a very noisy problem and classification accuracy
based on a training set of all 443 samples is only estimated to be around
56%–60%.
In order to evaluate the performance of our approach using modifications
of the lasso, we next applied our EIV method using the elastic net [Zou and
Hastie (2005)] to the lung cancer data set. In 3 of the 5 resampled data
sets of size 200, the results were almost identical to the lasso; in one case
(data set 5) the ratio of the estimate to its standard deviation was below
the 0.5 cutoff for all sample sizes less than 183 and, not surprisingly, our
method did not work in that case; in another resampled data set (data set
3), our method produced larger sample size estimates for the elastic net than
the lasso. Details are shown in the Supplemental Material [Safo, Song and
Dobbin (2015)].
4.3. Prostate cancer microarray data set. We next applied our method
to the prostate cancer data set described in Dettling and Bu¨hlmann (2003).
This data set consisted of a total of 102 human samples, 52 from prostate
tumors and 50 from nontumor prostate tissue samples. Intuitively, we may
expect that classification of samples into tumor versus nontumor would be
a relatively easy problem. For this data set, the EIV sample size estimates
for tolerances of 0.10, 0.30, 0.50 were 164, 119 and 103, respectively. Inter-
estingly, these results suggest that the sample size used (102) for the pilot
study is inadequate for producing a classifier with a tolerance closer than
0.50 to the optimal value. The cross-validated misclassification rates for the
prostate cancer data set reported in the (2003) paper ranged from 4.9%
to 13.7%. The average of 20 resamplings from our approach resulted in an
estimated β102 = 3.55, corresponding to an error rate of 14%. In this applica-
tion, the estimated β∞ averaged over 20 resamplings was 4.16 with standard
error 0.12; the 4.16 corresponds to an error rate of 12%. Note that here the
relatively large tolerance of 0.5 is associated with a small increase in accu-
racy because the asymptotic slope estimate is relatively large. In conclusion,
our method produces results that are in accord with intuition in that the
sample size used produces a classifier with accuracy close to the optimal for
this easier classification problem. But we also observed large fluctuations
in the β∞ estimate when the resampled data sets were between 51 and 93,
which suggests that the asymptotic estimate of a 12% error rate is quite un-
stable. We won’t speculate as to the cause of this instability, but intuitively
one would expect that a smaller error rate would be possible. Importantly,
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the instability of the asymptotic estimate does not seem to compromise the
sample size estimate.
4.4. The RNA-seq data set. We performed a proof of principle study to
see if these methods could be applied effectively to RNA-seq data. First,
note that RNA-seq data after being processed may be in the form of counts
(e.g., from the Myrna algorithm), but are more often in the form of contin-
uous values (e.g., normalized Myrna data, or FPKM fragments-per-kilobase
of exon per million fragments mapped from Cufflinks or other software).
Therefore, linear models with continuous high-dimensional predictors are
reasonable to use for RNA-seq data. But it is important to check that the
processed data appear reasonably Gaussian and, if not, to transform the
data.
We applied the LC and EIV methods to the Drosophila melanogaster
data of Graveley et al. (2011). Processed data were downloaded from the
ReCount database [Frazee, Langmead and Leek (2011)]. Variables with more
than 50% missing data were removed. Remaining data were truncated below
at 1.5 and log-transformed. Low variance features were filtered out, resulting
in p = 500 dimensions. Since this was a highly controlled experiment with
large biological differences between the fly states, some class distinctions
resulted in separable classes. Logistic regression is not appropriate for per-
fectly separated data. Samples were split into two classes: Class 1 consisted
of all the embryos and some adult and white prepupae (WPP); Class 2 con-
sisted of all the larvae and a mix of adults and WPP. The class sizes were 82
and 65. A principal component plot is shown in the Supplement [Safo, Song
and Dobbin (2015)]. The data set consisted of a total of npilot = 147 data
points. Technical replicates in the data created a clustering pattern visible
in principal components plots. This type of clustering is often observed in
cancer patient data sets due to disease subgroupings. We did not attempt to
adjust the analysis for the technical replicates. The resulting EIV method
equation for the sample size was
nˆ= 105.73− 14.25
(
t−0.3434 − 1
(−0.3434)
)
.
For tolerances of 0.1, 0.05 and 0.02, sample size estimates were 156, 180 and
223, respectively. The cross-validated accuracy, averaged over 10 replica-
tions, was 91%. Based on the βˆ∞ = 4.55, the optimal accuracy is 88.5%, and
the full data set accuracy is 88%, corresponding to βˆ147 = 4.42 = 4.55 −
T̂ol(147). The conditional score was used for the EIV method. The LC
method curve was err = 0.075+1.252×n−0.9122321 . The asymptotic accuracy
estimate is 92.5%, corresponding to β∞ = 7.2, and the estimated accuracy
when n= 147 is 91.2%, corresponding to βn = 6.1. The LC sample size es-
timates for tolerances of 0.10, 0.05 and 0.02 were 1,383, 8,361 and 13,342,
20 S. SAFO, X. SONG AND K. K. DOBBIN
respectively. As with the simulation studies, the LC method estimates are
much larger than the EIV estimates.
The difference in performance of the two methods on the RNA-seq data
is probably attributable to reduced noise on this data set, resulting in a set
of genes with large differences between the classes relative to the noise level
present. This may make the fly data set similar to some of the simulated
data sets, where large differences were observed between LC and EIV per-
formance. This different structure of the data compared to the microarray
data sets may be due to the larger biological variability between the fly
states, or a reduction in noise variation due to the RNA-seq platform, or a
combination of both.
5. Discussion. In this paper we studied the problem of sample size esti-
mation for regularized logistic regression classification in cancer. Two meth-
ods of sample size estimation were studied in simulations and applications.
The simulation results suggested that the EIV method works well and that
the LC method sometimes works but is sometimes overly conservative. The
methods were applied to a lymphoma data set, a lung cancer data set, a
prostate cancer data set and an RNA-seq data set. The results in lym-
phoma and lung cancer suggest that these studies had adequate sample
sizes already, and that larger studies are unlikely to yield better classifiers.
For the prostate cancer data set, the analysis revealed that the pilot data
set size was inadequate, resulting in high variation in the predicted classifi-
cation scores. The RNA-seq data analysis showed that the EIV method also
appears to work well on this type of data, but a critical problem is the lack of
publicly available and accessible RNA-seq data sets that could serve as pilot
data sets. This observation highlights a critical existing log-jam in medical
research, the problem of the lack of availability of RNA-seq data sets (or
modified versions thereof) for study planning purposes. In the meantime,
existing microarray data sets and/or simulated data sets must be used for
RNA-seq study planning.
A new sample size method for training regularized logistic regression-
based classifiers was developed. The method exploits a structural similarity
between logistic prediction and errors-in-variables regression models. The
method was shown to perform well when an adequate pilot data set is avail-
able. Methods for assessing the adequacy of a pilot data set were developed.
If no adequate pilot data set is available, the method can be used with Monte
Carlo samples from a parametric simulation.
An important issue in using either the LC or EIV method is the fitting of
the curve that produces the final sample size estimate. In the LC method,
as described in Mukherjee et al. (2003), a constrained least squares opti-
mization must be performed on a nonlinear regression model. Constrained
optimization methods like the L-BFGS-B algorithm used in the application
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of the Mukherjee et al. (2003) method in this paper may produce different
solutions than standard, unconstrained least squares optimization methods
such as Nelder–Mead. In contrast, the Box–Cox algorithm and linear regres-
sion fitting used by our approach are more straightforward to implement.
Because our method does not need to “extrapolate to infinity” as the typical
learning curve method requires, the regression model is chosen that fits the
best in the vicinity of the data points. This simplifies the fitting procedure,
albeit at the cost of the errors-in-variables regression step. For both meth-
ods, it is advisable to look at the final plot of the fitted line and the data
points as a basic regression diagnostic.
The reader may have noted that the variance parameter σ2n =Varn(Uij)
is estimated by bootstrapping the pilot data set. But the variance is defined
as a variance across independent training sets of size n in the population.
Since the bootstrap data sets will have overlap, obviously there is potential
bias in the bootstrap estimation procedure. Whether the bootstrap could be
modified to reduce this bias is a potential area for future work.
If more than two classes are present in the data, then simple regularized
logistic regression is no longer an appropriate analysis strategy. In order to
apply our method in that setting, regularized methods for more than two
classes would need to be developed, for example, regularized multinomial or
ordinal logistic regression methods. Also, corresponding errors-in-variables
methods for these multi-class logistic regression methods would be needed.
It appears that both these would be prerequisites to such an extension.
If classes are completely separable in the high-dimensional space, then
regularized logistic regression is not advisable because the logistic regression
slope will be undefined and the logistic fitting algorithms will become unsta-
ble. The approach presented in this paper cannot be used in that context.
In this paper we have focused simulations on settings with equal preva-
lence from each class. If the class prevalences are unequal, then the method
can still be applied as presented in the paper—as was done in the applica-
tions to the real data sets, for example. However, if the imbalance is large
(e.g., 90% versus 10%), then the training set size required by our Condition 1
in Section 2.5 would likely be excessive. But, in this case, it is also less likely
that accuracy will be the objective criteria for model selection because a
high accuracy may be associated with a classifier that puts most subjects in
the majority class. Ideally, positive and negative predictive values and their
associated clinical implications would likely be more useful criteria. This is
a potential future direction of research.
SUPPLEMENTARY MATERIAL
Supplemental tables, figures, algorithms, details and discussion (DOI:
10.1214/15-AOAS825SUPP; .pdf). Supplemental material for paper by Safo,
Song and Dobbin.
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